Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

被引:195
作者
Estey, Elihu
de Lima, Marcos
Tibes, Raoul
Pierce, Sherry
Kantarjian, Hagop
Champlin, Richard
Giralt, Sergio
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA
关键词
D O I
10.1182/blood-2006-05-021907
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To prospectively assess the applicability of reduced-intensity conditioning hematopoletic stem cell transplantation (RIC-HSCT), we wrote a protocol in which all untreated patients 50 years or older with acute myelold leukemia (AML) and unfavorable cytogenetics would be evaluated during induction for a possible RIC-HSCT in first complete remission (CR1). Ninety-nine of 259 patients entered CR. Fifty-three of the 99 were seen by the Transplant Service with the remainder not seen because of illness, lack/unavailability of siblings, refusal, or, primarily, unclear reasons (21 patients). A donor was identified for 26 patients (21 sibling, 5 unrelated) with RIC-HSCT performed in 14 (13 sibling). Results in consulted patients suggested that 50% or fewer of the 85 patients who did not undergo transplantation were potential transplant candidates. We attempted to find one or more chemotherapy pair-mates for each patient who underwent transplantation based on cytogenetics, age, and a relapse-free survival (RFS) time that was more than or equal to the time from CR1 to RIC-HSCT in the patient who under-went transplantation. Thirty-two of the 39 matches favored (longer RFS) RIC-HSCT and 7, chemotherapy. The probability that the corresponding beta distribution was different than expected (i.e, that RIC-HSCT was superior) was 0.99 (P =.004). Results were similar with respect to survival. While RIC-HSCT thus seems of interest, methods are needed to extend its applicability.
引用
收藏
页码:1395 / 1400
页数:6
相关论文
共 25 条
[1]  
BERRY D, 1996, STAT BAYESIAN APPROA, P200
[2]   The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial [J].
Burnett, AK ;
Wheatley, K ;
Goldstone, AH ;
Stevens, RF ;
Hann, IM ;
Rees, JHK ;
Harrison, G .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) :385-400
[3]   Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].
Cassileth, PA ;
Harrington, DP ;
Appelbaum, FR ;
Lazarus, HM ;
Rowe, JM ;
Paietta, E ;
Willman, C ;
Hurd, DD ;
Bennett, JM ;
Blume, KG ;
Head, DR ;
Wiernik, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656
[4]   Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation [J].
de Lima, M ;
Anagnostopoulos, A ;
Munsell, M ;
Shahjahan, M ;
Ueno, N ;
Ippoliti, C ;
Andersson, BS ;
Gajewski, J ;
Couriel, D ;
Cortes, J ;
Donato, M ;
Neumann, J ;
Champlin, R ;
Giralt, S .
BLOOD, 2004, 104 (03) :865-872
[5]   Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors [J].
Diaconescu, R ;
Flowers, CR ;
Storer, B ;
Sorror, ML ;
Maris, MB ;
Maloney, DG ;
Sandmaier, BM ;
Storb, R .
BLOOD, 2004, 104 (05) :1550-1558
[6]   Plausibility of delaying induction therapy in untreated AML. [J].
Estey, EH ;
Wang, XM ;
Thall, P ;
Pierce, S ;
Koller, C ;
Faderl, S ;
Verstovsek, S ;
Cortes, J ;
Garcia-Manero, G ;
Kantarjian, H .
BLOOD, 2004, 104 (11) :251A-251A
[7]   New designs for phase 2 clinical trials [J].
Estey, EH ;
Thall, PF .
BLOOD, 2003, 102 (02) :442-448
[8]   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy [J].
Giralt, S ;
Estey, E ;
Albitar, M ;
vanBesien, K ;
Rondon, G ;
Anderlini, P ;
OBrien, S ;
Khouri, I ;
Gajewski, J ;
Mehra, R ;
Claxton, D ;
Andersson, B ;
Beran, M ;
Przepiorka, D ;
Koller, C ;
Kornblau, S ;
Korbling, M ;
Keating, M ;
Kantarjian, H ;
Champlin, R .
BLOOD, 1997, 89 (12) :4531-4536
[9]   Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial [J].
Goldstone, AH ;
Burnett, AK ;
Wheatley, K ;
Smith, AG ;
Hutchinson, RM ;
Clark, RE .
BLOOD, 2001, 98 (05) :1302-1311
[10]  
GRAY R, 1991, BONE MARROW TRANSPL, V7, P9